

local, and Territorial health departments in order for them to make contact with individuals who may have been exposed to a communicable disease during travel and identify appropriate next steps.

Section 361 of the Public Health Service Act (42 U.S.C. 264) authorizes the Secretary of the Department of Health and Human Services to make and enforce regulations necessary to prevent the introduction, transmission, or spread of communicable diseases from foreign countries into the United States, or from one State or possession into any other State or possession. Regulations that implement Federal quarantine authority are currently promulgated in 42 CFR parts 70 and 71. Part 71 contains regulations to prevent the introduction, transmission, and spread of communicable diseases into the States and possessions of the United States, while part 70 contains regulations to prevent the introduction, transmission, or spread of communicable diseases from one State into another.

Passenger and crew manifests contain certain information for travelers on an aircraft and are generally collected from airlines when a communicable disease is confirmed after the air travel has been completed. Manifests include locating

and contact information, as well as information concerning where passengers sat while aboard the aircraft. The specific list of data elements included in the domestic manifest order is:

- Full name (last, first, and, if available, middle or others);
- Date of birth;
- Sex;
- Country of residence;
- If a passport is required; passport number, passport country of issuance, and passport expiration date;
- If a travel document, other than a passport is required, travel document type, travel document number, travel document country of issuance and travel document expiration date;
- Address while in the United States (number and street, city, State, and zip code), except that U.S. citizens and lawful permanent residents will provide address of permanent residence in the U.S. (number and street, city, State, and zip code; as applicable);
- Primary contact phone number to include country code;
- Secondary contact phone number to include country code;
- Email address;
- Airline name;
- Flight number;
- City of departure;

- Departure date and time;
- City of arrival;
- Arrival date and time; and
- Seat number for all passengers

CDC also requests seat configuration for the requested contact area (example: AB/aisle/CDE/aisle/FG, bulkhead in front of row 9), identification on the manifest of the crew and what zone crew were assigned to, the identification of any babies-in-arms, and finally CDC requests the total number of passengers on board if measles is the cause of the investigation, due to the highly infectious nature of the disease.

CDC then uses this passenger and crew manifest information to coordinate with State and local health departments so they can follow up with residents who live or are currently located in their jurisdiction. In most cases, the manifests are issued for air travel, and State and local health departments or IHR NFPs are responsible for the contact investigations; airlines may take responsibility for the follow-up of crew members. In rare cases, CDC may use the manifest data to perform the contact investigation directly.

CDC requests OMB approval for an estimated 3,240 annual burden hours. There are no costs to respondents other than their time to participate.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Airline Medical Officer or Equivalent/Airline Administrative or Safety Manager	Domestic Manifest Order Template	500	1	6
Airline Administrative or Safety Manager	Informal Manifest Request	25	1	6
Traveler	Public Health Passenger Locator Form: limited onboard exposure (International Flights).	545	1	5/60
Traveler	Public Health Passenger Locator Form: limited onboard exposure (Domestic Flights).	545	1	5/60

Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2024-05770 Filed 3-18-24; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund Rwanda Biomedical Center (RBC)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and

Human Services (HHS), announces the award of approximately \$17,500,000, for Year 1 funding to RBC. The award will support a sustainable, affordable, integrated, and country-led HIV/AIDS clinical and public health program in Rwanda. Funding amounts for years 2-5 will be set at continuation.

DATES: The period for this award will be September 30, 2024, through September 29, 2029.

FOR FURTHER INFORMATION CONTACT: Antyme Kayisabe, Center for Global Health, Centers for Disease Control and Prevention, 30 KG 7 Avenue (Kacyiru), P.O. Box 28 Kigali, Rwanda, telephone: 788382114, e-Mail: hqq9@cdc.gov.

SUPPLEMENTARY INFORMATION: The sole source award will support the government of Rwanda's vision of achieving and maintaining HIV epidemic control and the UNAIDS goal of ending HIV/AIDS as a public health threat by 2030.

RBC is in a unique position to conduct this work, as it possesses not only the mandate but also has the capacities to manage donor funds efficiently and in accordance with PEPFAR principles and United State Government regulations. All health workers implementing PEPFAR-supported HIV clinical services including HIV testing, Antiretroviral Therapy, TB/HIV, prevention of mother to child transmission, and laboratory services are Ministry of Health (MOH) staff. All health facilities where PEPFAR-supported services are offered are under RBC accreditation and authorization. RBC is successfully coordinating HIV services in all health facilities countrywide. It is the only entity capable of providing comprehensive services and integrating HIV into the national health system to cover all Rwanda districts at each level.

Summary of the Award

Recipient: Rwanda Biomedical Center (RBC).

Purpose of the Award: The purpose of this award is to support a sustainable, affordable, integrated, and country-led HIV/AIDS clinical and public health program in Rwanda.

Amount of Award: For RBC, the approximate year 1 funding amount will be \$17,500,000 in Federal Fiscal Year (FFY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) (22 U.S.C. 7601, *et seq.*) and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

Period of Performance: The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

Jamie Legier,

Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.

[FR Doc. 2024–05776 Filed 3–18–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund National Tuberculosis Control Program (NTCP)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award(s) of approximately \$3,000,000, for Year 1 funding to NTCP. The award will improve the capacity of the health system at national, regional, district, and facility levels to provide an effective public health response for Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection in Cameroon, reduce disease burden, and contribute to achieving and sustaining epidemic control. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2024, through September 29, 2029.

FOR FURTHER INFORMATION CONTACT: F.E. Harrison, Center for Global Health, Centers for Disease Control and Prevention, telephone: (404) 639–6095, email: ckv3@cdc.gov.

SUPPLEMENTARY INFORMATION: This sole source award will accelerate progress in reducing the burden of TB and TB/HIV co-infection in Cameroon through a multistakeholder approach.

NTCP is in a unique position to conduct this work, as it is the only institution that has the legal mandate to develop and implement the national strategic plan for TB control, which aims to reduce the morbidity and mortality associated with TB.

Summary of the Award

Recipient: National Tuberculosis Control Program (NTCP).

Purpose of the Award: The purpose of this award is to improve the capacity of the health system at national, regional, district, and facility levels to provide an effective public health response for TB and HIV co-infection in Cameroon, reduce disease burden, and contribute to achieving and sustaining epidemic control.

Amount of Award: For NTCP, the approximate year 1 funding amount will be \$3,000,000 in Federal Fiscal Year

(FFY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) (22 U.S.C. 7601, *et seq.*) and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

Period of Performance: The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

Jamie Legier,

Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.

[FR Doc. 2024–05772 Filed 3–18–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund World Health Organization (WHO)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$20,000,000, for Year 1 funding to WHO. This award will support the development of global guidelines and provide technical assistance through WHO to aid PEPFAR-supported countries to meet the 95–95–95 targets and achieve program sustainability by 2030. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this this award will be September 30, 2024, through September 29, 2029

FOR FURTHER INFORMATION CONTACT: Francheskie Velez, Center for Global Health, Centers for Disease Control and Prevention, 1600 Clifton Road NE MS–E39 Atlanta, GA 30329, telephone: 404.245.5639, e-Mail: gpg2@cdc.gov.

SUPPLEMENTARY INFORMATION: The sole source award will support efforts to improve surveillance, prevention, care, and treatment of HIV, Tuberculosis (TB), sexually transmitted infection